Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, United States.
Mississippi Center of Excellence in Perinatal Research, University of Mississippi Medical Center, Jackson, MS, United States.
Front Endocrinol (Lausanne). 2023 Feb 15;14:951099. doi: 10.3389/fendo.2023.951099. eCollection 2023.
Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. PCOS is characterized by androgen excess, oligo/anovulation, and polycystic appearance of the ovaries. Women with PCOS have an increased prevalence of multiple cardiovascular risk factors such as insulin resistance, hypertension, renal injury, and obesity. Unfortunately, there is a lack of effective, evidence-based pharmacotherapeutics to target these cardiometabolic complications. Sodium-glucose cotransporter-2 (SGLT2) inhibitors provide cardiovascular protection in patients with and without type 2 diabetes mellitus. Although the exact mechanisms of how SGLT2 inhibitors confer cardiovascular protection remains unclear, numerous mechanistic hypotheses for this protection include modulation of the renin-angiotensin system and/or the sympathetic nervous system and improvement in mitochondrial function. Data from recent clinical trials and basic research show a potential role for SGLT2 inhibitors in treating obesity-associated cardiometabolic complications in PCOS. This narrative review discusses the mechanisms of the beneficial effect of SGLT2 inhibitors in cardiometabolic diseases in PCOS.
多囊卵巢综合征（PCOS）是生育期妇女最常见的内分泌疾病。PCOS 的特征是雄激素过多、排卵障碍和多囊卵巢。患有 PCOS 的女性更容易出现多种心血管危险因素，如胰岛素抵抗、高血压、肾损伤和肥胖。不幸的是，目前缺乏针对这些代谢并发症的有效、基于证据的药物治疗方法。钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂在有或没有 2 型糖尿病的患者中均能提供心血管保护。尽管 SGLT2 抑制剂发挥心血管保护作用的确切机制尚不清楚，但这种保护的许多机制假说包括调节肾素-血管紧张素系统和/或交感神经系统以及改善线粒体功能。来自最近的临床试验和基础研究的数据表明，SGLT2 抑制剂在治疗 PCOS 相关肥胖合并的心血管代谢并发症方面具有潜在作用。本文讨论了 SGLT2 抑制剂在 PCOS 代谢性心血管疾病中的有益作用的机制。
